Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway - 28/03/23



Abstract |
Glioblastoma (GBM) is a human malignant tumor with low survival and high recurrence rate. Angelicin, an active furanocoumarin compound, has been reported to possess potential antitumor activity towards various malignancies. However, the effect of angelicin on GBM cells and its mechanism are still unclear. In this study, we found that angelicin inhibited the proliferation of GBM by inducing the cell cycle arrested in G1 phase and suppressed the migration of GBM cells in vitro. Mechanically, we found that angelicin downregulated the expression of YAP and decreased the nuclear localization of YAP, and suppressed the expression of β-catenin. Furthermore, overexpression of YAP partially restored the inhibitory effect of angelicin on GBM cells in vitro. Finally, we found that angelicin could inhibit the growth of tumor and reduce the expression of YAP in the subcutaneous xenograft model of GBM in nude mice and the syngeneic intracranial orthotopic model of GBM in C57BL/6 mice. Taken together, our results suggest that the natural product angelicin exerts its anticancer effects on GBM via YAP signaling pathway, and is expected to be a promising compound for the treatment of GBM.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Angelicin inhibits the proliferation and migration of GBM cells in vitro. |
• | Angelicin decreases the expression and nucleus translocation of YAP in vitro. |
• | YAP overexpression partly abolishes the inhibitory effect of angelicin in vitro. |
• | Angelicin inhibits the growth of GBM and reduces the YAP expression in vivo. |
Abbreviations : Ang, GBM, YAP
Keywords : Angelicin, GBM, YAP, Proliferation, Cell cycle, Migration
Plan
Vol 161
Article 114462- mai 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?